Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2011

View Archived Issues

123I-DRM-106 to be developed for SPECT imaging of amyloid plaques

Micro-NMR operated by smart phone for accurate diagnosis of malignant tumors

Pioglitazone reduces the formation of renal stones in rats

Karo Bio and Zydus Cadila extend glucocorticoid research collaboration

Benefits reported for fesoterodine in elderly patients with overactive bladder

XenoPort reports data from phase IIb arbaclofen placarbil trial in GERD

Phase IIa clinical trial of NasVax's anti-CD3 MAb immunotherapy meets all endpoints

NKTR-181 displays reduced CNS side effect potential compared to oxycodone

Six-month data show improvements in childhood hypophosphatasia with ENB-0040

Novel tubulisine derivatives for cancer prepared at KemoTech

Sanofi-aventis patents new series of tryptase inhibitors

United Therapeutics' FREEDOM-C(2) registration trial for UT-15C fully enrolled

FDA assigns PDUFA date to Shire's resubmission of Firazyr for treatment of HAE

Ipilimumab improves overall survival in phase III trial in metastatic melanoma

New phosphatidylcholine transfer protein inhibitors patented by Brigham & Women's Hospital

Intellikine scientists synthesize novel PI3K inhibitors

Alzheimer's Drug Discovery Foundation supports ADispell's neuroprotective drug research

Seattle Genetics forms antibody-drug conjugate collaboration with Abbott

Cellerant Therapeutics begins phase I/II CLT-008 trial for neutropenia in leukemia

Johns Hopkins patents novel inhibitors of LSD1 for cancer

Quest Diagnostics signs agreement to acquire Celera

Provectus and FDA hold second end-of-phase II meeting on PV-10 for melanoma

Tesaro acquires rights to Amgen's anaplastic lymphoma kinase program

Aradigm completes enrollment in phase IIb inhaled ciprofloxacin trial

Asahi Kasei obtains exclusive rights to Xiaflex for two indications in Japan

FDA extends review of Novartis's NDA for QAB-149, a once-daily bronchodilator for COPD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...